These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 14718091)

  • 21. The Emergence of Reduced Ciprofloxacin Susceptibility in Salmonella enterica Causing Bloodstream Infections in Rural Ghana.
    Eibach D; Al-Emran HM; Dekker DM; Krumkamp R; Adu-Sarkodie Y; Cruz Espinoza LM; Ehmen C; Boahen K; Heisig P; Im J; Jaeger A; von Kalckreuth V; Pak GD; Panzner U; Park SE; Reinhardt A; Sarpong N; Schütt-Gerowitt H; Wierzba TF; Marks F; May J
    Clin Infect Dis; 2016 Mar; 62 Suppl 1():S32-6. PubMed ID: 26933017
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Emergence and properties of fluoroquinolone resistant Salmonella enterica serovar Typhi strains isolated from Nepal in 2002 and 2003.
    Nobthai P; Serichantalergs O; Wongstitwilairoong B; Srijan A; Bodhidatta L; Malla S; Mason CJ
    Southeast Asian J Trop Med Public Health; 2010 Nov; 41(6):1416-22. PubMed ID: 21329318
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rapid detection of gyrA and parC mutations in quinolone-resistant Salmonella enterica using Pyrosequencing technology.
    Hopkins KL; Arnold C; Threlfall EJ
    J Microbiol Methods; 2007 Jan; 68(1):163-71. PubMed ID: 16934351
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of a LightCycler gyrA mutation assay for rapid identification of mutations conferring decreased susceptibility to ciprofloxacin in multiresistant Salmonella enterica serotype Typhimurium DT104 isolates.
    Walker RA; Saunders N; Lawson AJ; Lindsay EA; Dassama M; Ward LR; Woodward MJ; Davies RH; Liebana E; Threlfall EJ
    J Clin Microbiol; 2001 Apr; 39(4):1443-8. PubMed ID: 11283069
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of an acrR mutation in multidrug resistance of in vitro-selected fluoroquinolone-resistant mutants of Salmonella enterica serovar Typhimurium.
    Olliver A; Vallé M; Chaslus-Dancla E; Cloeckaert A
    FEMS Microbiol Lett; 2004 Sep; 238(1):267-72. PubMed ID: 15336432
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Joint effects of topoisomerase alterations and plasmid-mediated quinolone-resistant determinants in Salmonella enterica Typhimurium.
    Luo Y; Li J; Meng Y; Ma Y; Hu C; Jin S; Zhang Q; Ding H; Cui S
    Microb Drug Resist; 2011 Mar; 17(1):1-5. PubMed ID: 20818995
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alterations in the GyrA and GyrB subunits of topoisomerase II and the ParC and ParE subunits of topoisomerase IV in ciprofloxacin-resistant clinical isolates of Pseudomonas aeruginosa.
    Lee JK; Lee YS; Park YK; Kim BS
    Int J Antimicrob Agents; 2005 Apr; 25(4):290-5. PubMed ID: 15784307
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mutant prevention concentrations for single-step fluoroquinolone-resistant mutants of wild-type, efflux-positive, or ParC or GyrA mutation-containing Streptococcus pneumoniae isolates.
    Smith HJ; Walters M; Hisanaga T; Zhanel GG; Hoban DJ
    Antimicrob Agents Chemother; 2004 Oct; 48(10):3954-8. PubMed ID: 15388458
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characterization of the mechanisms of fluoroquinolone resistance in vancomycin-resistant enterococci of different origins.
    López M; Tenorio C; Del Campo R; Zarazaga M; Torres C
    J Chemother; 2011 Apr; 23(2):87-91. PubMed ID: 21571624
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular characterization of fluoroquinolone resistance in nontypeable Haemophilus influenzae clinical isolates.
    Puig C; Tirado-Vélez JM; Calatayud L; Tubau F; Garmendia J; Ardanuy C; Marti S; de la Campa AG; Liñares J
    Antimicrob Agents Chemother; 2015 Jan; 59(1):461-6. PubMed ID: 25385097
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
    Chen S; Cui S; McDermott PF; Zhao S; White DG; Paulsen I; Meng J
    Antimicrob Agents Chemother; 2007 Feb; 51(2):535-42. PubMed ID: 17043131
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fluoroquinolone resistance in Streptococcus pneumoniae: evidence that gyrA mutations arise at a lower rate and that mutation in gyrA or parC predisposes to further mutation.
    Gillespie SH; Voelker LL; Ambler JE; Traini C; Dickens A
    Microb Drug Resist; 2003; 9(1):17-24. PubMed ID: 12705679
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Resistance to fluoroquinolones linked to gyrA and par C mutations and overexpression of acr AB efflux pump in Salmonella enterica serotype Choleraesuis.
    Chu C; Su LH; Chu CH; Baucheron S; Cloeckaert A; Chiu CH
    Microb Drug Resist; 2005; 11(3):248-53. PubMed ID: 16201927
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Functional characterization of quinolone-resistant mechanisms in a lab-selected Salmonella enterica typhimurium mutant.
    Gu Y; Xu X; Lin L; Ren X; Cui X; Hou X; Cui S
    Microb Drug Resist; 2013 Feb; 19(1):15-20. PubMed ID: 23013383
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mutant prevention concentrations of ciprofloxacin and enrofloxacin for Salmonella enterica.
    Randall LP; Cooles SW; Piddock LJ; Woodward MJ
    J Antimicrob Chemother; 2004 Sep; 54(3):688-91. PubMed ID: 15243029
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of intra- and extragenic compensatory mutations in the suppression of fluoroquinolone resistance in a Salmonella Typhimurium gyrA mutant (D87G).
    Preisler A; Heisig P
    J Antimicrob Chemother; 2009 Feb; 63(2):290-4. PubMed ID: 19033246
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The acquisition of full fluoroquinolone resistance in Salmonella Typhi by accumulation of point mutations in the topoisomerase targets.
    Turner AK; Nair S; Wain J
    J Antimicrob Chemother; 2006 Oct; 58(4):733-40. PubMed ID: 16895934
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Detection of mutations in Salmonella enterica gyrA, gyrB, parC and parE genes by denaturing high performance liquid chromatography (DHPLC) using standard HPLC instrumentation.
    Randall LP; Coldham NG; Woodward MJ
    J Antimicrob Chemother; 2005 Oct; 56(4):619-23. PubMed ID: 16141278
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular characterization of ciprofloxacin-resistant Salmonella enterica serovar Typhi and Paratyphi A causing enteric fever in India.
    Gaind R; Paglietti B; Murgia M; Dawar R; Uzzau S; Cappuccinelli P; Deb M; Aggarwal P; Rubino S
    J Antimicrob Chemother; 2006 Dec; 58(6):1139-44. PubMed ID: 17071955
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A new therapeutic challenge for old pathogens: community-acquired invasive infections caused by ceftriaxone- and ciprofloxacin-resistant Salmonella enterica serotype choleraesuis.
    Ko WC; Yan JJ; Yu WL; Lee HC; Lee NY; Wang LR; Chuang YC
    Clin Infect Dis; 2005 Jan; 40(2):315-8. PubMed ID: 15655754
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.